Neuroone Medical Technologies (NMTC) Change in Accured Expenses (2013 - 2026)

Neuroone Medical Technologies has disclosed Change in Accured Expenses across 14 years of filings, most recently posting $31133.0 for Q1 2026.

• Quarterly Change in Accured Expenses fell 4.35% year-over-year to $31133.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$211941.0 (down 3841.9% YoY) and the FY2025 annual result came in at -$54442.0, down 435.77% from the prior year.
• Change in Accured Expenses climbed to $31133.0 in Q1 2026, from -$619376.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.7 million in Q3 2022 and bottomed at -$1.4 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $73839.0 (2025), against an average of -$5853.6.
• Year-over-year, Change in Accured Expenses surged 1227.97% in 2022 and slumped 7447.94% in 2023.
• Neuroone Medical Technologies' Change in Accured Expenses stood at -$306125.0 in 2022, then slumped by 69.4% to -$518584.0 in 2023, then increased by 10.66% to -$463292.0 in 2024, then sank by 33.69% to -$619376.0 in 2025, then soared by 105.03% to $31133.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered $31133.0, -$619376.0, and $302463.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.